Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482053 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00482053: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00482053 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00482053, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if double autologous then allogeneic hematopoietic cell transplant may offer an improved treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional transplantation regimen.
Primary Outcome
Event-free survival (EFS) through 4 years, as assessed in participants with poor-risk recurrent or primary refractory DLBCL treated with TLI and ATG followed by matched allogeneic hematopoietic cell transplantation as a consolidation to HCT. Event is defined as tumor progression or death.
Interventions
- DRUG Rituximab
- DRUG Carmustine
- PROCEDURE Autologous hematopoietic stem cell transplantation (auto-HSCT)
- PROCEDURE Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
- PROCEDURE Total lymphoid irradiation (TLI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Why NCT00482053 stopped before completion
NCT00482053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT00482053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00482053 about?
NCT00482053 is a clinical study titled "Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT". The purpose of this study is to determine if double autologous then allogeneic hematopoietic cell transplant may offer an improved treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional transplantation regimen.
What is the current status of trial NCT00482053?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2006-10. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00482053?
The interventions under investigation include: Rituximab (DRUG), Carmustine (DRUG), Autologous hematopoietic stem cell transplantation (auto-HSCT) (PROCEDURE), Allogeneic hematopoietic stem cell transplantation (allo-HSCT) (PROCEDURE), Total lymphoid irradiation (TLI) (PROCEDURE).
Who is sponsoring clinical trial NCT00482053?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00482053's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia